Shares of NRx Pharmaceuticals slid after the company proposed a public offering of its common stock.
The stock retreated 19% to $3.74 after hours. Shares had gained 70% year-to-date when the market closed.
The biopharmaceutical company said after the closing bell Tuesday that it intends to offer an unspecified number of shares. It would use the proceeds for working capital and general corporate purposes to support growth.
NRx said it would grant the offering's underwriter a 30-day option to buy an additional 14% of the shares it sells during the offering.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
June 02, 2026 17:15 ET (21:15 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments